Member Exclusive

Cancer drug development halted following trial deaths

Mirna Therapeutics Inc. (Austin, TX, USA) halts drug development of its flag-ship oncology drug MRX34 following adverse trial results, culminating with the deaths of clincal trial participants.

Go to the profile of RxNet
Nov 16, 2016

Please sign in or register for FREE

Register to RxNet

RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.


No comments yet.